Form 4: Benitec Biopharma Inc. Grants Stock Options to J. Kevin Buchi

Benitec Biopharma Inc. has granted stock options to J. Kevin Buchi, exercisable for 35,000 shares of common stock, vesting no later than December 9, 2025.

Summary

• Benitec Biopharma Inc. granted stock options to J. Kevin Buchi on December 9, 2024.
• The options are for 35,000 shares of common stock.
• The exercise price of the options is $12.18 per share.
• The options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action of granting stock options, which is generally viewed positively as it aligns management interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options may serve as an incentive for J. Kevin Buchi.
• The vesting schedule aligns with the company's annual stockholder meeting or a fixed date, which is a common practice.

Risks

• The value of the options is dependent on the future performance of Benitec Biopharma's stock price.
• If the stock price does not increase above the exercise price, the options may not be valuable to the recipient.

Future Outlook

The vesting of the options is contingent on the company's next annual stockholders' meeting or December 9, 2025, whichever comes first.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key personnel and align their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation in the biotech industry, often used to attract and retain talent.
• The vesting period of approximately one year is typical for such grants.
• The exercise price is set at the market price at the time of the grant, which is a common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management.
• The grant has a potential dilutive effect on existing shareholders if the options are exercised.

Next Steps

• The options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025.

Key Dates

Keywords

stock options, equity compensation, common stock, vesting, Benitec Biopharma, J. Kevin Buchi